Clearside Biomedical Inc (CLSD)
1.035
+0.02
(+2.48%)
USD |
NASDAQ |
Nov 04, 16:00
1.06
+0.02
(+2.42%)
After-Hours: 20:00
Clearside Biomedical Enterprise Value: 46.13M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 46.13M |
| October 31, 2024 | 46.88M |
| October 30, 2024 | 48.38M |
| October 29, 2024 | 49.12M |
| October 28, 2024 | 52.86M |
| October 25, 2024 | 52.86M |
| October 24, 2024 | 52.86M |
| October 23, 2024 | 55.48M |
| October 22, 2024 | 59.21M |
| October 21, 2024 | 69.30M |
| October 18, 2024 | 56.60M |
| October 17, 2024 | 56.60M |
| October 16, 2024 | 54.36M |
| October 15, 2024 | 53.61M |
| October 14, 2024 | 59.59M |
| October 11, 2024 | 63.32M |
| October 10, 2024 | 69.30M |
| October 09, 2024 | 68.56M |
| October 08, 2024 | 81.26M |
| October 07, 2024 | 88.74M |
| October 04, 2024 | 79.02M |
| October 03, 2024 | 70.05M |
| October 02, 2024 | 70.80M |
| October 01, 2024 | 70.80M |
| September 30, 2024 | 65.57M |
| Date | Value |
|---|---|
| September 27, 2024 | 57.34M |
| September 26, 2024 | 55.85M |
| September 25, 2024 | 54.36M |
| September 24, 2024 | 56.22M |
| September 23, 2024 | 60.33M |
| September 20, 2024 | 68.56M |
| September 19, 2024 | 66.31M |
| September 18, 2024 | 67.81M |
| September 17, 2024 | 68.18M |
| September 16, 2024 | 68.56M |
| September 13, 2024 | 62.58M |
| September 12, 2024 | 71.55M |
| September 11, 2024 | 68.56M |
| September 10, 2024 | 55.10M |
| September 09, 2024 | 49.87M |
| September 06, 2024 | 43.14M |
| September 05, 2024 | 39.96M |
| September 04, 2024 | 42.40M |
| September 03, 2024 | 45.39M |
| August 30, 2024 | 46.13M |
| August 29, 2024 | 46.13M |
| August 28, 2024 | 45.39M |
| August 27, 2024 | 46.13M |
| August 26, 2024 | 46.13M |
| August 23, 2024 | 46.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.810M
Minimum
Dec 21 2022
401.84M
Maximum
Aug 27 2021
89.02M
Average
63.07M
Median
Apr 26 2022
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.191B |
| Arcus Biosciences Inc | 448.13M |
| Crinetics Pharmaceuticals Inc | 3.674B |
| Biomea Fusion Inc | 239.65M |
| NovaBay Pharmaceuticals Inc | 3.615M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.594M |
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 7.68M |
| EPS Diluted (Quarterly) | -0.10 |
| Profit Margin (Quarterly) | -8.44K% |
| Earnings Yield | -48.54% |
| Normalized Earnings Yield | -48.54 |